{"url_path":"/sec/oprx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1448431/0001448431-26-000011-index.html","accession_number":"0001448431-26-000011","cik":"0001448431","ticker":"OPRX","issuer_name":"OptimizeRx Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1448431/0001448431-26-000011-index.html","primary_entity_key":"0001448431","primary_entity_name":"OptimizeRx Corp"},"word_count":497,"has_tables":true,"body_markdown":"oprx-20260331\n000144843112-312026Q1falsexbrli:sharesiso4217:USDiso4217:USDxbrli:sharesoprx:segmentxbrli:pureoprx:facilityoprx:planoprx:contract00014484312026-01-012026-03-3100014484312026-04-2900014484312026-03-3100014484312025-12-310001448431us-gaap:TreasuryStockCommonMember2026-03-3100014484312025-01-012025-03-310001448431us-gaap:CommonStockMember2025-12-310001448431us-gaap:TreasuryStockCommonMember2025-12-310001448431us-gaap:AdditionalPaidInCapitalMember2025-12-310001448431us-gaap:RetainedEarningsMember2025-12-310001448431us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001448431oprx:IncentivePlanOneMemberus-gaap:CommonStockMember2026-01-012026-03-310001448431us-gaap:CommonStockMember2026-01-012026-03-310001448431us-gaap:RetainedEarningsMember2026-01-012026-03-310001448431us-gaap:CommonStockMember2026-03-310001448431us-gaap:CommonStockMember2024-12-310001448431us-gaap:TreasuryStockCommonMember2024-12-310001448431us-gaap:AdditionalPaidInCapitalMember2024-12-310001448431us-gaap:RetainedEarningsMember2024-12-3100014484312024-12-310001448431us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001448431us-gaap:CommonStockMember2025-01-012025-03-310001448431us-gaap:RetainedEarningsMember2025-01-012025-03-310001448431us-gaap:CommonStockMember2025-03-310001448431us-gaap:TreasuryStockCommonMember2025-03-310001448431us-gaap:AdditionalPaidInCapitalMember2025-03-310001448431us-gaap:RetainedEarningsMember2025-03-3100014484312025-03-310001448431us-gaap:PatentsMember2026-03-310001448431us-gaap:PatentsMember2026-01-012026-03-310001448431us-gaap:TechnologyBasedIntangibleAssetsMember2026-03-310001448431us-gaap:TechnologyBasedIntangibleAssetsMember2026-01-012026-03-310001448431us-gaap:CustomerRelationshipsMember2026-03-310001448431us-gaap:CustomerRelationshipsMember2026-01-012026-03-310001448431us-gaap:PatentsMember2025-12-310001448431us-gaap:PatentsMember2025-01-012025-12-310001448431us-gaap:TechnologyBasedIntangibleAssetsMember2025-12-310001448431us-gaap:TechnologyBasedIntangibleAssetsMember2025-01-012025-12-310001448431us-gaap:CustomerRelationshipsMember2025-12-310001448431us-gaap:CustomerRelationshipsMember2025-01-012025-12-3100014484312025-01-012025-12-3100014484312023-10-112023-10-110001448431oprx:MedicsHealthMember2023-10-112023-10-110001448431oprx:TermLoanMember2023-10-1100014484312023-10-110001448431oprx:FirstAnniversaryMember2023-10-110001448431oprx:SecondAnniversaryMember2023-10-110001448431oprx:ThirdAnniversaryMember2023-10-110001448431oprx:ExcessCashFlowMultiplierTwentyFivePercentageFactorMember2023-10-110001448431oprx:ExcessCashFlowMultiplierFiftyPercentageFactorMember2023-10-110001448431oprx:ExcessCashFlowMultiplierFiftyPercentageFactorMembersrt:MinimumMember2023-10-110001448431oprx:ExcessCashFlowMultiplierFiftyPercentageFactorMembersrt:MaximumMember2023-10-110001448431oprx:ExcessCashFlowMultiplierSeventyFivePercentageFactorMember2023-10-110001448431srt:MaximumMember2023-10-110001448431us-gaap:FederalFundsEffectiveSwapRateMember2023-10-110001448431us-gaap:SecuredOvernightFinancingRateSofrMember2023-10-110001448431us-gaap:PrimeRateMember2023-10-110001448431oprx:MarginRateMember2023-10-110001448431oprx:TermLoanMember2026-03-310001448431oprx:TermLoanMember2026-01-012026-03-310001448431us-gaap:PreferredStockMember2026-03-310001448431oprx:IncentivePlanOneMember2026-01-012026-03-310001448431oprx:IncentivePlanOneMemberus-gaap:CommonStockMember2025-01-012025-03-310001448431oprx:IncentivePlanOneMember2025-01-012025-03-3100014484312024-03-310001448431oprx:TwoThousandThirteenIncentivePlanMember2026-03-310001448431oprx:TwoThousandThirteenIncentivePlanMemberus-gaap:StockOptionMember2026-03-310001448431oprx:TwoThousandThirteenIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2026-03-310001448431oprx:TwoThousandTwentyOneIncentivePlanMember2024-06-052024-06-050001448431oprx:TwoThousandTwentyOneIncentivePlanMember2024-06-050001448431oprx:TwoThousandTwentyOneIncentivePlanMemberus-gaap:StockOptionMember2026-03-310001448431oprx:TwoThousandTwentyOneIncentivePlanMemberus-gaap:RestrictedStockUnitsRSUMember2026-03-310001448431oprx:TwoThousandTwentyOneIncentivePlanMember2026-03-310001448431us-gaap:StockOptionMember2026-01-012026-03-310001448431us-gaap:StockOptionMember2025-01-012025-03-310001448431us-gaap:StockOptionMember2026-03-310001448431us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001448431us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001448431srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001448431us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMember2026-03-310001448431us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2025-03-310001448431srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001448431us-gaap:TransferredOverTimeMember2026-01-012026-03-310001448431us-gaap:TransferredOverTimeMember2025-01-012025-03-310001448431us-gaap:TransferredAtPointInTimeMember2026-01-012026-03-310001448431us-gaap:TransferredAtPointInTimeMember2025-01-012025-03-3100014484312011-01-012011-12-310001448431oprx:EversanaMember2026-01-012026-03-310001448431oprx:EversanaMember2025-01-012025-03-310001448431us-gaap:StockOptionMember2026-01-012026-03-310001448431us-gaap:StockOptionMember2025-01-012025-03-310001448431us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001448431us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001448431oprx:NewTermLoanMemberus-gaap:SubsequentEventMember2026-05-070001448431us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMember2026-05-070001448431oprx:TermLoanMemberus-gaap:SubsequentEventMember2026-05-070001448431us-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMemberus-gaap:SubsequentEventMember2026-05-072026-05-070001448431us-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMemberus-gaap:SubsequentEventMember2026-05-072026-05-07\n\n[Table of Contents](#i676fe0a0881d4aa987d10830578e4845_7)\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, DC 20549\n\nFORM 10-Q\n\nx Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934\n\nFor the quarterly period ended March 31, 2026\n\no Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934\n\nFor the transition period from __________ to __________\n\nCommission File Number: 001-38543\n\nOptimizeRx Corporation\n\n(Exact name of registrant as specified in its charter)\n\nNevada26-1265381\n\n(State or other jurisdiction of\n incorporation or organization)(IRS Employer\n Identification No.)\n\n260 Charles Street, Suite 302\n\nWaltham, MA 02453\n\n(Address of principal executive offices)\n\n248-651-6568\n\n(Registrant’s telephone number, including area code)\n\n(Former name, former address and former fiscal year, if changed since last report)\n\nSecurities registered under Section 12(b) of the Exchange Act:\n\nTitle of each classTrading Symbol(s)Name of each exchange on which registered\n\nCommon Stock, par value $0.001OPRX\nNasdaq Capital Market\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\noLarge accelerated fileroAccelerated filer\n\nxNon-accelerated filerxSmaller reporting company\n\noEmerging growth company\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x\n\nState the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 18,765,075 common shares as of April 29, 2026.\n\n[Table of Contents](#i676fe0a0881d4aa987d10830578e4845_7)\n\nTABLE OF CONTENTS\n\nPage\n\n[PART I – FINANCIAL INFORMATION](#i676fe0a0881d4aa987d10830578e4845_10)\n\n[Item 1:](#i676fe0a0881d4aa987d10830578e4845_13)\n\n[Financial Statements](#i676fe0a0881d4aa987d10830578e4845_13)\n\n[1](#i676fe0a0881d4aa987d10830578e4845_13)\n\n[Item 2:](#i676fe0a0881d4aa987d10830578e4845_70)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#i676fe0a0881d4aa987d10830578e4845_70)\n\n[20](#i676fe0a0881d4aa987d10830578e4845_70)\n\n[Item 3:](#i676fe0a0881d4aa987d10830578e4845_100)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#i676fe0a0881d4aa987d10830578e4845_100)\n\n[26](#i676fe0a0881d4aa987d10830578e4845_100)\n\n[Item 4:](#i676fe0a0881d4aa987d10830578e4845_103)\n\n[Controls and Procedures](#i676fe0a0881d4aa987d10830578e4845_103)\n\n[26](#i676fe0a0881d4aa987d10830578e4845_103)\n\n[PART II — OTHER INFORMATION](#i676fe0a0881d4aa987d10830578e4845_106)\n \n\n[Item 1:](#i676fe0a0881d4aa987d10830578e4845_109)\n\n[Legal Proceedings](#i676fe0a0881d4aa987d10830578e4845_109)\n\n[28](#i676fe0a0881d4aa987d10830578e4845_109)\n\n[Item 1A:](#i676fe0a0881d4aa987d10830578e4845_112)\n\n[Risk Factors](#i676fe0a0881d4aa987d10830578e4845_112)\n\n[28](#i676fe0a0881d4aa987d10830578e4845_112)\n\n[Item 2:](#i676fe0a0881d4aa987d10830578e4845_115)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#i676fe0a0881d4aa987d10830578e4845_115)\n\n[28](#i676fe0a0881d4aa987d10830578e4845_115)"}